Wiendl, Heinz and Gold, Ralf and Berger, Thomas and Derfuss, Tobias and Linker, Ralf and Maeurer, Mathias and Stangel, Martin and Aktas, Orhan and Baum, Karl and Berghoff, Martin and Bittner, Stefan and Chan, Andrew and Czaplinski, Adam and Deisenhammer, Florian and Di Pauli, Franziska and Du Pasquier, Renaud and Enzinger, Christian and Fertl, Elisabeth and Gass, Achim and Gehring, Klaus and Gobbi, Claudio and Goebels, Norbert and Guger, Michael and Haghikia, Aiden and Hartung, Hans-Peter and Heidenreich, Fedor and Hoffmann, Olaf and Hunter, Zoe R. and Kallmann, Boris and Kleinschnitz, Christoph and Klotz, Luisa and Leussink, Verena and Leutmezer, Fritz and Limmroth, Volker and Luenemann, Jan D. and Lutterotti, Andreas and Meuth, Sven G. and Meyding-Lamade, Uta and Platten, Michael and Rieckmann, Peter and Schmidt, Stephan and Tumani, Hayrettin and Weber, Martin S. and Weber, Frank and Zettl, Uwe K. and Ziemssen, Tjalf and Zipp, Frauke (2021) Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper). NERVENARZT, 92 (8). pp. 773-801. ISSN 0028-2804, 1433-0407
Full text not available from this repository. (Request a copy)Abstract
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, Switzerland).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STEM-CELL TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; 1ST DEMYELINATING EVENT; 5-YEAR FOLLOW-UP; INTERFERON BETA-1A; INTRAMUSCULAR INTERFERON; CLINICALLY DEFINITE; ORAL CLADRIBINE; OPEN-LABEL; JC VIRUS; Autoimmune-mediated disease; Immunotherapy; Early therapeutic intervention; Treatment recommendation; Guideline |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 26 Sep 2022 08:32 |
| Last Modified: | 26 Sep 2022 08:32 |
| URI: | https://pred.uni-regensburg.de/id/eprint/47976 |
Actions (login required)
 |
View Item |
